Sanofi Stops Development of Amcenestrant.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      FRANCE
    • Subject Terms:
      UNITED States. Food & Drug Administration
    • Abstract:
      The article reports on the discontinuation of the global clinical development program of amcenestrant, an oral selective estrogen receptor degrader (SERD), after a failed trial in advanced breast cancer, by Sanofi, a pharmaceutical industry company.